Abstracts tagged "Inflammation"

Abstract Number: 1649 • ACR Convergence 2020
Effect of Knee Aspiration and Intra-articular Corticosteroid Injection on Gait Biomechanics and Strength Impairment in Patients with Signs of Inflammation Due to Knee Osteoarthritis
Ryan Pinto¹, Trevor Birmingham¹, Holly Philpott², Dominique Arsenault¹, Codie Primeau¹ and Tom Appleton³, ¹Western University, London, Canada, ²Western University, London, ON, Canada, ³The University of Western Ontario, LONDON, ON, Canada
Background/Purpose: Synovial inflammation in knees with OA can be measured with musculoskeletal ultrasound (MSK US), is associated with increased pain and disease progression, and may…
Abstract Number: PP10 • ACR Convergence 2020
Patients with Relapsing Polychondritis (“RP”) and an Advocate Manufactured Custom Cloth Masks to Combat COVID-19: This Mask Project Provided a Sense of Purpose, Created Unity, Increased Awareness of RP, Facilitated Research, and Generated Hope
Isabel Bautista¹ and Michael Linn², ¹Relapsing Polychondritis Foundation, Wilmington, CA, ²Relapsing Polychondritis Foundation, New York, NY

Background/Purpose: In 2013, I was diagnosed with Relapsing Polychondritis ("RP"), a systemic inflammatory disease of unknown etiology that can be fatal. The disease affects multiple…
Abstract Number: 0069 • ACR Convergence 2020
Identification of CD13 as a Potential Cause for SARS-CoV-2-triggered Hyperinflammation and Thrombosis
Eliza Pei-Suen Tsou¹, Gautam Sule¹, Mikel Gurrea Rubio², M. Asif Amin¹, Yu Zuo¹, Jason Knight¹, Yogendra Kanthi³ and David Fox¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Canton, MI, ³Division of Cardiovascular Medicine, Ann Arbor
Background/Purpose: The ectopeptidase CD13, which is highly expressed on stromal and myeloid cells in joints, lung and other tissues, is a known receptor for many…
Abstract Number: 0449 • ACR Convergence 2020
Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca
Blake Warner¹, Billel Gasmi², David Kleiner³, Paola Perez Riveros⁴, Daniel Barber⁵, Shunsuke Sakai⁵ and Alan Baer⁶, ¹National Institute of Dental and Craniofacial Research, Bethesda, ²National Cancer Institute, Bethesda, MD, ³National Cancer Institute, Bethesda, ⁴National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁵National Institute of Allergy and Infectious Disease, Bethesda, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICI) have advanced the field of cancer therapeutics. By blocking the negative co-stimulation of T cells, ICI augment the anti-tumor immune…
Abstract Number: 0739 • ACR Convergence 2020
Toll-like Receptor Inhibitor Peptide Improves the Clinical, Immunologic, and Pathologic Manifestations of Systemic Lupus Erythematosus
Chang-Hee Suh¹, Wook-Young Baek¹, Ji-Won Kim¹, Yang-Seon Choi², Sung-Min Lee¹, In-Ok Son¹, Ki-Woong Jeon¹ and Sangdun Choi², ¹Ajou University School of Medicine, Suwon, Republic of Korea, ²Ajou University, Suwon, Republic of Korea
Background/Purpose: Toll-like receptors (TLRs) are a type of protein that plays a major role in the innate immune system. In recent years, several studies have…
Abstract Number: 0967 • ACR Convergence 2020
Absence of Thy1 Associated with Severe Bone Loss in the TNF-transgenic (TNF-Tg) Mice Arthritis Model
Ananta Paine¹, Maria de la Luz Garcia-Hernandez², Marc Nuzzo³, Stacey Duemmel³, Benjamin Korman¹ and Christopher Ritchlin¹, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Department of Medicine, University of Rochester Medical Center, West Henrietta, NY, ³Department of Medicine, University of Rochester Medical Center, Rochester
Background/Purpose: Thy1 (CD90) is a glycosylated, glycophosphatidylinositol (GPI)-anchored membrane protein noted to be expressed on many cells including T lymphocytes, stem cells, osteoblasts and fibroblasts.…
Abstract Number: 1337 • ACR Convergence 2020
Relationship of the Pro12Ala Polymorphism of the PPARg Gene with Inflammatory Activity, Osteoporosis and Obesity in Patients with Psoriatic Arthritis
Olga Compán¹, Maria Elisa Acosta², Sonia Pastor², Guadalupe Manzano Canabal², Luis Gomez-Lechon Quiros³, Cristina Hidalgo Calleja⁴, Noelia Cubino², Ricardo Usategui⁵, Rogelio Gonzalez Sarmiento⁵, Olga Martinez Gonzalez⁶, Ana Isabel Turrión², Javier Del Pino-Montes² and Carlos Montilla Morales², ¹Hospital Universitario de Salamanca, ´Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ⁴Hospital Universitario Salamanca, Salamanca, Spain, ⁵Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain, ⁶Hospital Universitario de Salamanca, Zamora, Spain
Background/Purpose: In the pathogenesis of psoriatic arthritis (PsA), increased inflammatory cytokines lead to increased RANGO-L activity and stimulation of osteoclasts, leading to osteoporosis. This comorbidity,…
Abstract Number: 1692 • ACR Convergence 2020
Poor Physical Activity Levels and Cardiorespiratory Fitness Among Patients with Childhood-Onset Takayasu Arteritis in Remission
Camilla Astley¹, Saulo Gil², Gleice Clemente³, Maria Teresa Terreri⁴, Lucia Campos⁵, Nadia Aikawa⁵, Ana Lucia de-Sá Pinto², Rosa Pereira⁵, Hamilton Roschel² and Bruno Gualano², ¹University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²University of Sao Paulo, Sao paulo, Brazil, ³Federal University of Sao Paulo, Sao Paulo, Brazil, ⁴Federal University of São Paulo, São Paulo, Brazil, ⁵Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Childhood-onset Takayasu Arteritis (c-TA) is a rare, granulomatous, chronic large-vessel vasculitis that involves mostly the aorta and its major branches with a high mortality…
Abstract Number: 0070 • ACR Convergence 2020
Neutrophils Transiting Through Megakaryocytes During Emperipolesis Exhibit Distinct Fates and Acquire the Capacity to Guide Other Neutrophils via MK Trails
Frank Huang¹, Pierre Cunin², Felix Radtke³, Ricardo Grieshaber-Bouyer⁴, Roxane Darbousset⁵ and Peter Nigrovic⁶, ¹Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany, Darmstadt, Baden-Wurttemberg, Germany, ²Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany, Boston, ⁴Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany, ⁵Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁶Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston
Background/Purpose: Megakaryocytes (MKs) can contribute directly to experimental arthritis via pro-inflammatory microparticles containing IL-1 (Cunin et al. Journal of Clinical Investigation, 2017). MKs also interact…
Abstract Number: 0450 • ACR Convergence 2020
In Vitro Characterization of Inflammatory Arthritis Associated with Immune Check Point Inhibition
Anne Sofie Sørensen¹, Morten Nørgaard Andersen¹, Kristian Juul-Madsen², Cæcilie Deisting Skejø¹, Henrik Schmidt¹, Thomas Vorup-Jensen¹ and Tue Wenzel Kragstrup¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University, Aarhus, Midtjylland, Denmark
Background/Purpose: During treatment with immune checkpoint inhibitors (ICI) such as the anti-PD-1 antibody pembrolizumab, 2-4% of cancer patients develop inflammatory arthritis as an immune-related adverse…
Abstract Number: 0749 • ACR Convergence 2020
Locating Cellular Subsets in Rheumatoid Arthritis Synovium Using CO-Detection by IndEXing (CODEX)
Isabella Wulur¹, David Boyle², Lin Zhang¹, Andrea Martin¹, Robert Benschop³ and Gary Firestein⁴, ¹Eli Lilly, Indianapolis, IN, ²UC San Diego, San Diego, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: To better understand site-of-disease mechanisms in arthritis, the phenotypes and organization of synovial cells and infiltrates are critical. Conventional histology-based approaches are limited in…
Abstract Number: 1037 • ACR Convergence 2020
Relationship Between Air Quality and Sarcoidosis Inflammatory Activity
Aaron Case¹, Dustin Fraidenburg², Israel Rubinstein² and Christian Ascoli², ¹University of Illinois at Chicago, Chicago, IL, ²Division of Pulmonary,Critical Care, Sleep and Allergy; Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA, Chicago, IL
Background/Purpose: African Americans [AA] and minorities in the lower socioeconomic strata of Chicago are disproportionately affected by pulmonary sarcoidosis, and regularly exposed to poorer air…
Abstract Number: 1374 • ACR Convergence 2020
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
Bruce Kirkham¹, Peter Nash², Sandra Navarra³, Erhard Quebe-Fehling⁴, Corine Gaillez⁴, Carlos Sastre⁴ and Philip Mease⁵, ¹Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Santo Tomas, Manila, Philippines, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed…
Abstract Number: 1697 • ACR Convergence 2020
Immune Related Adverse Events from Checkpoint Inhibitor Therapy: Survey of Hospitalists’ Awareness and Experiences
Cassandra Calabrese¹, Alexa Meara² and Varalakshmi Janamanchi¹, ¹Cleveland Clinic, Cleveland, OH, ²Ohio State University Wexner School of Medicine, Columbus, OH
Background/Purpose: The introduction of immunologic checkpoint inhibitor therapy (ICI) has caused a paradigm shift in the world of cancer treatment. Their use, however, is attended…
Abstract Number: 0073 • ACR Convergence 2020
A Cross-Species Map of Neutrophil Inflammatory Responses
Felix Radtke¹, Frank Huang², Peter Nigrovic³ and Ricardo Grieshaber-Bouyer⁴, ¹Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany, Heidelberg, Baden-Wurttemberg, Germany, ²Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany, Darmstadt, Baden-Wurttemberg, Germany, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁴Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany
Background/Purpose: Neutrophils are important mediators of immune defense as well as key protagonists in immune-mediated disease. How these cells adapt differently to sterile and septic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].